Abstract
Bacillus Calmette Guerin (BCG) vaccine is still the only licensed vaccine against Tuberculosis (TB), with an estimated global coverage of 85%. However, although the vaccine has been established, discussions about its benefits and shortcomings continue.The coverage of immunization is appropriate with the target, but still the occurrence of child TB cases raises a problem of its own. This studywas a non-experimental study with study design was Case Control Study by retrospective. The effectiveness of BCG immunization in this study is 85%, meaning that children are given BCG 85% immunization will be protected from Tuberculocis (TB) disease. If the child does not get BCG immunization will increase the chances for the child, with OR = 6.87 (95% CI; 2.2 – 21.1) with p value = 0.000. It is suggested to Banyuasin regency Health Office to conduct the contact examination of house of children who are around TB positive patients periodically (monthly / at posyandu).
Highlights
Bacillus Calmette Guerin (BCG) vaccine is still the only licensed vaccine against Tuberculosis (TB), with an estimated global coverage of 85% [1.2]
6.87 2.2 – 21.1 In Table 1, it was found that 21 (84%) of children diagnosed with TB were not given BCG immunization, and for BCG immunized children 55 (43.3%) of children diagnosed with TB
P = 0,000, it can be concluded that there was a difference of proportion in TB incidence between BCG immunized child and BCG immunization
Summary
Bacillus Calmette Guerin (BCG) vaccine is still the only licensed vaccine against Tuberculosis (TB), with an estimated global coverage of 85% [1.2]. Even Indonesia, since 1956, has implemented an immunization program, one of which is BCG vaccination. The Ministry of Health is implementing the Immunization Development Program (PPI) for children in efforts to reduce the incidence of diseases that can be prevented by immunization (PD3I) [3]. The presence of different BCG strains and immunization policies that took place several decades prior to the release of such global recommendations have made it difficult to assess the efficacy of BCG vaccine. The vaccine has been established, discussions about its benefits and shortcomings continue.The issues discussed include vaccine safety aspects, loss of sensitivity to tuberculin as a diagnostic reagent, and the fact that it has been shown to help end the TB Epidemic in Europe, the efficacy of this vaccine is generally disappointing in trials conducted in developing countries [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
